Research analysts at Maxim Group initiated coverage on shares of Medicenna Therapeutics (TSE:MDNA – Get Rating) in a report released on Tuesday, TipRanks reports. The firm set a “buy” rating and a C$4.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 173.97% from the company’s previous close.
Several other brokerages also recently issued reports on MDNA. HC Wainwright reiterated a “buy” rating and issued a C$7.00 price target on shares of Medicenna Therapeutics in a report on Thursday, February 10th. Brookline Capital Acquisition increased their price target on Medicenna Therapeutics to C$14.00 and gave the company a “buy” rating in a report on Wednesday, April 13th.
Shares of TSE MDNA opened at C$1.46 on Tuesday. Medicenna Therapeutics has a 12-month low of C$1.35 and a 12-month high of C$4.90. The company has a market cap of C$81.13 million and a P/E ratio of -3.10. The company has a current ratio of 11.07, a quick ratio of 10.21 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average price of C$1.63 and a 200 day moving average price of C$2.08.
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.